Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

Preventivt arbete kan minska läkemedelsbiverkningar.

Hallberg P, Collin S, Wadelius M.

Lakartidningen. 2017 Jul 14;114. pii: ERYW. Swedish. No abstract available.

PMID:
28718862
2.

Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema.

Rasmussen ER, von Buchwald C, Wadelius M, Prasad SC, Kamaleswaran S, Ajgeiy KK, Authried G, Pallesen KA, Bygum A.

Int J Otolaryngol. 2017;2017:1476402. doi: 10.1155/2017/1476402. Epub 2017 Feb 14.

3.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.

Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M.

Clin Pharmacol Ther. 2017 Feb 15. doi: 10.1002/cpt.668. [Epub ahead of print]

PMID:
28198005
4.

Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.

Hallberg P, Persson M, Axelsson T, Cavalli M, Norling P, Johansson HE, Yue QY, Magnusson PK, Wadelius C, Eriksson N, Wadelius M.

Pharmacogenomics. 2017 Feb;18(3):201-213. doi: 10.2217/pgs-2016-0184. Epub 2017 Jan 13.

5.

Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.

Baranova EV, Verhoef TI, Ragia G, le Cessie S, Asselbergs FW, de Boer A, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group.

J Thromb Haemost. 2017 Mar;15(3):465-472. doi: 10.1111/jth.13615. Epub 2017 Feb 17.

PMID:
28063245
6.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.

Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.

7.

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.

Fung P, Bedogni G, Bedogni A, Petrie A, Porter S, Campisi G, Bagan J, Fusco V, Saia G, Acham S, Musto P, Petrucci MT, Diz P, Colella G, Mignogna MD, Pentenero M, Arduino P, Lodi G, Maiorana C, Manfredi M, Hallberg P, Wadelius M, Takaoka K, Leung YY, Bonacina R, Schiødt M, Lakatos P, Taylor T, De Riu G, Favini G, Rogers SN, Pirmohamed M, Nicoletti P; GENVABO Consortium, Fedele S.

Oral Dis. 2017 May;23(4):477-483. doi: 10.1111/odi.12632. Epub 2017 Mar 6.

PMID:
28039941
8.

Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.

Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group.

J Thromb Haemost. 2017 Mar;15(3):454-464. doi: 10.1111/jth.13601. Epub 2017 Feb 17.

PMID:
27992949
9.

Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough.

Hallberg P, Nagy J, Karawajczyk M, Nordang L, Islander G, Norling P, Johansson HE, Kämpe M, Hugosson S, Yue QY, Wadelius M.

Ann Pharmacother. 2017 Apr;51(4):293-300. doi: 10.1177/1060028016682251. Epub 2016 Nov 26.

PMID:
27889699
10.

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.

Eriksson N, Wallentin L, Berglund L, Axelsson T, Connolly S, Eikelboom J, Ezekowitz M, Oldgren J, Paré G, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Yusuf S, Wadelius M.

Pharmacogenomics. 2016 Aug;17(13):1425-39. doi: 10.2217/pgs-2016-0061. Epub 2016 Aug 4.

11.

Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.

Verhoef TI, Redekop WK, Langenskiold S, Kamali F, Wadelius M, Burnside G, Maitland-van der Zee AH, Hughes DA, Pirmohamed M.

Pharmacogenomics J. 2016 Oct;16(5):478-84. doi: 10.1038/tpj.2016.41. Epub 2016 Jun 7.

PMID:
27272045
12.

Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population.

Hallberg P, Eriksson N, Ibañez L, Bondon-Guitton E, Kreutz R, Carvajal A, Lucena MI, Ponce ES, Molokhia M, Martin J, Axelsson T, Yue QY, Magnusson PK, Wadelius M; EuDAC collaborators.

Lancet Diabetes Endocrinol. 2016 Jun;4(6):507-16. doi: 10.1016/S2213-8587(16)00113-3. Epub 2016 May 3.

PMID:
27157822
13.

Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis.

Yu WY, Sun X, Wadelius M, Huang L, Peng C, Ma WL, Yang GP.

Cardiovasc Ther. 2016 Oct;34(5):297-307. doi: 10.1111/1755-5922.12186. Review.

PMID:
27062534
14.

HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.

Nicoletti P, Werk AN, Sawle A, Shen Y, Urban TJ, Coulthard SA, Bjornsson ES, Cascorbi I, Floratos A, Stammschulte T, Gundert-Remy U, Nelson MR, Aithal GP, Daly AK; International Drug-induced Liver Injury Consortium.

Pharmacogenet Genomics. 2016 May;26(5):218-24. doi: 10.1097/FPC.0000000000000209.

PMID:
26959717
15.

Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose.

Cavalli M, Pan G, Nord H, Eriksson N, Wadelius C, Wadelius M.

Pharmacogenomics. 2016 Aug;17(12):1305-14. doi: 10.2217/pgs-2015-0013. Epub 2016 Feb 5.

16.

Genome-wide association study of warfarin maintenance dose in a Brazilian sample.

Parra EJ, Botton MR, Perini JA, Krithika S, Bourgeois S, Johnson TA, Tsunoda T, Pirmohamed M, Wadelius M, Limdi NA, Cavallari LH, Burmester JK, Rettie AE, Klein TE, Johnson JA, Hutz MH, Suarez-Kurtz G.

Pharmacogenomics. 2015;16(11):1253-63. doi: 10.2217/PGS.15.73. Epub 2015 Aug 12.

17.

Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.

Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Maitland-van der Zee AH; EU-PACT group; members of the EU-PACT group are.

Thromb Res. 2015 Jul;136(1):94-100. doi: 10.1016/j.thromres.2015.04.034. Epub 2015 May 2.

PMID:
25971661
18.

Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants.

Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH; EU-PACT consortium.

Thromb Res. 2015 Jul;136(1):69-75. doi: 10.1016/j.thromres.2015.04.026. Epub 2015 Apr 25.

PMID:
25956287
19.

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children.

Hamberg AK, Hellman J, Dahlberg J, Jonsson EN, Wadelius M.

BMC Med Inform Decis Mak. 2015 Feb 7;15:7. doi: 10.1186/s12911-014-0128-0.

20.

Oral anticoagulation: a critique of recent advances and controversies.

Pirmohamed M, Kamali F, Daly AK, Wadelius M.

Trends Pharmacol Sci. 2015 Mar;36(3):153-63. doi: 10.1016/j.tips.2015.01.003. Epub 2015 Feb 17. Review.

PMID:
25698605

Supplemental Content

Loading ...
Support Center